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Randomised Comparison of Aboral Pouch with Preserved Duodenal Passage to
Oral Pouch with Preserved Duodenal Passage
Regarding the postoperative, basic anthropometric and laboratory parameters no
significant difference has been demonstrated between Aboral Pouch with Preserved
Duodenal Passage (APwPDP) and Oral Pouch with Preserved Duodenal Passage
(OPwPDP) patients (table 1).
Table 1: Basic anthropometric and laboratory parameters in Trial-III
APwPDP OPwPDP p
n: 14 13
Body weight (start) 61,33 ± 1,72 66,10 ± 1,97 0,08
BMI (start) 22,57 ± 0,57 24,19 ± 0,62 0,07
Protein (start) 65,09 ± 2,85 64,97 ± 2,53 0,97
Albumin (start) 33,05 ± 1,58 35,41 ± 1,76 0,32
Triglicerid (start) 1,75 ± 0,18 1,99 ± 0,22 0,40
Cholesterol (start) 4,93 ± 0,35 4,78 ± 0,25 0,74
Hemoglobin (start) 113,24 ±5,57 114,39 ± 3,76 0,87
Iron (start) 8,35 ± 2,05 7,77 ± 1,36 0,82
Transferrine sat % (start) 9,70 ± 3,33 14,57 ± 2,27 0,25
Transferrine (start) 2,30 ± 0,19 2,03 ± 0,20 0,35
IgA (start) 2,61 ± 0,46 3,00 ± 0,38 0,54
IgG (start) 8,37 ± 0,97 9,02 ± 0,78 0,62
IgM (start) 1,18 ± 0,24 1,55 ± 0,19 0,26
OPNI (start) 43,84 ± 1,78 45,83 ± 3,69 0,62
Anthropometric measurements: As represented in table 2, no significant
difference has been found in body weight, body mass index (BMI) and change in BMI
in percentage of the postoperative BMI 6, 12 and 24 months after surgery between
groups APwPDP and OPwPDP.
Table 2: Results of nutritional, laboratory, motility, absorption and quality of life
measurements in Trial-III. Significant differences were found in serum protein level at 6
months, serum albumin at 6, 12 and 24 months, immunoglobuline-A level at 24 months
and in the number of meals taken per day at 6 months. P values for ANOVA are
represented. Post hoc test results revealing the source of difference are detailed in the
text.
Trial-III APwPDP OPwPDP p
n: 14 13
Body weight – 6 months 60,81 ± 2,02 60,60 ± 2,09 0,95
Body weight – 12 months 61,71 ± 2,27 61,00 ± 3,76 0,86
Body weight – 24 months 61,18 ± 2,57 62,00 ± 4,22 0,86
BMI – 6 months 22,31 ± 0,55 22,22 ± 0,73 0,92
BMI – 12 months 22,68 ± 0,71 22,68 ± 0,97 0,99
BMI – 24 months 23,13 ± 0,97 22,66 ± 1,17 0,76
BMI % – 6 months 99,14 ± 2,76 92,69 ± 3,63 0,16
BMI % – 12 months 99,43 ± 2,74 94,61 ± 4,65 0,38
BMI % – 24 months 98,91 ± 2,72 96,05 ± 5,11 0,64
Protein – 6 months 73,22 ± 1,34 69,81 ± 0,74 0,05
Protein – 12 months 72,92 ± 1,29 72,18 ± 1,66 0,72
Protein – 24 months 74,63 ± 0,75 74,70 ± 1,73 0,61
Albumin – 6 months 41,50 ± 0,71 43,89 ± 1,01 0,05
Albumin – 12 months 42,10 ± 0,71 45,04 ± 1,26 0,04
Albumin – 24 months 42,76 ± 0,72 47,37 ± 1,55 0,007
Triglicerid – 6 months 1,32 ± 0,15 1,43 ± 0,16 0,61
Triglicerid – 12 months 1,32 ± 0,12 2,00 ± 0,65 0,23
Triglicerid – 24 months 1,38 ± 0,22 1,30 ± 0,16 0,79
Cholesterol – 6 months 5,14 ± 0,24 5,09 ± 0,22 0,89
Cholesterol – 12 months 5,46 ± 0,28 4,71 ± 0,36 0,11
Cholesterol – 24 months 5,69 ± 0,26 5,19 ± 0,30 0,24
Hemoglobin – 6 months 126,57 ± 4,02 125,18 ± 3,81 0,80
Hemoglobin – 12 months 128,00 ± 4,11 130,96 ± 4,49 0,63
Hemoglobin – 24 months 132,92 ± 3,00 132,22 ± 3,45 0,88
Iron – 6 months 16,74 ± 2,11 18,18 ± 1,48 0,60
Iron – 12 months 21,99 ± 2,42 18,29 ± 1,47 0,26
Iron – 24 months 21,39 ± 1,64 22,71 ± 1,38 0,58
Transferrine % – 6 mo. 22,87 ± 7,16 30,25 ± 3,37 0,31
Transferrine % – 12 mo. 29,87 ± 4,35 30,52 ± 3,64 0,91
Transferrine % – 24 mo. 29,00 ± 2,59 33,45 ± 3,73 0,32
Transferrine – 6 months 2,81 ± 0,19 2,66 ± 0,20 0,60
Transferrine – 12 months 3,00 ± 0,19 2,72 ± 0,20 0,34
Transferrine – 24 months 3,20 ± 0,15 2,95 ± 0,15 0,29
IgA – 6 months 3,29 ± 0,52 2,55 ± 0,33 0,29
IgA – 12 months 3,08 ± 0,52 2,53 ± 0,35 0,44
IgA – 24 months 3,75 ± 0,43 2,20 ± 0,28 0,01
IgG – 6 months 12,05 ± 0,99 10,40 ± 0,41 0,18
IgG – 12 months 10,81 ± 0,87 10,18 ± 0,56 0,60
IgG – 24 months 11,90 ± 0,80 10,71 ± 0,47 0,28
IgM – 6 months 1,03 ± 0,12 0,98 ± 0,15 0,82
IgM – 12 months 1,35 ± 0,24 1,03 ± 0,18 0,35
IgM – 24 months 1,55 ± 0,24 1,23 ± 0,19 0,37
OPNI – 6 months 53,27 ± 1,39 55,78 ± 2,93 0,41
OPNI – 12 months 54,79 ± 1,54 55,67 ± 1,86 0,71
OPNI – 24 months 54,90 ± 1,42 56,41 ± 1,66 0,50
GIQLI – 6 months 97,33 ± 4,29 91,11 ± 8,32 0,47
GIQLI – 12 months 106,00 ± 4,04 95,40 ± 6,81 0,16
GIQLI – 24 months 101,45 ± 5,73 101,78 ± 6,45 0,97
SSBP – 6 months 0,35 ± 0,08 0,33 ± 0,09 0,88
SSBP – 12 months 0,50 ± 0,10 0,28 ± 0,11 0,16
SSBP – 24 months 0,58 ± 0,12 0,39 ± 0,11 0,31
Lipiodol – 6 months 2,66 ± 0,16 3,23 ± 0,26 0,07
Lipiodol – 12 months 2,87 ± 0,19 3,45 ± 0,45 0,17
Lipiodol – 24 months 3,19 ± 0,38 3,75 ± 0,17 0,35
Xylose – 6 months 1072 ± 205 639 ± 112 0,11
Xylose – 12 months 1204 ± 185 905 ± 107 0,21
Xylose – 24 months 1257 ± 154 864 ± 111 0,06
No of meals – 6 months 4,88 ± 0,23 5,64 ± 0,15 0,02
No of meals – 12 months 5,13 ± 0,27 5,38 ± 0,26 0,57
No of meals – 24 months 5,25 ± 0,25 4,86 ± 0,34 0,36
Transferrin %: transferrin saturation in percentage, No of meals: number of meals per
day
Nutritional and immunologic laboratory measurements: Most of the measured
nutritional parameters followed similar pattern in the two groups, no significant
difference were found in regard of serum triglyceride, cholesterol, haemoglobin, iron,
transferrine and OPNI between the two groups (table 2). However serum albumin was
consequently, significantly higher in patients with an oral pouch at 6, 12 as well as 24
months follow-up (table 2). On the other hand serum protein was significantly higher in
aboral pouch group at 6 months and serum immunoglobulin-A was significantly higher
also in aboral pouch patients at 24 months.
Scintigraphic small bowel passage study (SSBP): No significant difference has
been demonstrated regarding the emptying rate of technecium-labelled test meal during
small bowel passage scintigraphy between the two groups.
Lipid and carbohydrate absorption tests: There was a tendency toward better
lipid absorption - tested by Lipiodol study - in oral pouch patients at 6 months, but is
disappeared by 12 months (table 2). And there was a tendency towards better
carbohydrate absorption – measured by Xylose test - in aboral pouch patients, which
appeared after 6 months and almost reached significant difference by 24 months (table
2). Nevertheless no significant difference has been demonstrated by absorption studies
between APwPDP and OPwPDP groups.
Quality of Life: The quality of life –tested by Eypash’s GIQLI – was similar in
both groups, slightly growing by time, but no difference has been observed between
groups (table 2).
The number of meals taken per day differed significantly at 6 months in favour
of aboral pouch, but the difference disappeared by time (table 2)
Discussion
The comparison of Aboral or Oral Pouch, both with preserved duodenal passage,
did not found any significant difference between the two groups regarding the primary
endpoints, i.e. body weight and quality of life has not been affected by the position of
the pouch during reconstruction after total gastrectomy.
Regarding the secondary endpoints some differences have been revealed. The
serum level of albumin was higher in Oral Pouch patients at 6, 12 as well as 24 months
postoperatively. It is difficult to find a clear cut explanation for this, especially in the
light of the fact, that serum protein levels were higher in the Aboral Pouch group
although only at 6 months, while serum Immunoglobulin-A levels were also higher in
Aboral Pouch group but at 24 months postoperatively. Thus these higher albumin levels
are not reflecting a better protein metabolism in Oral Pouch patients, in general. Serum
protein and albumin – as some of the most well known nutritional laboratory measures
– have been examined in some studies, but found to be affected in only few. Nakane et
al found a significantly higher protein level in patients with an Oral Pouch with
duodenal exclusion reconstruction compared to Roux-en-Y 12 and 24 but not 6 months
after surgery. They measured serum albumin too, and found no difference in albumin
levels comparing Oral Pouch with duodenal exclusion, Oral Pouch with duodenal
preservation and Roux-en-Y. In another trial, when they compared Oral Pouch with
duodenal passage preservation and Oral Pouch without duodenal passage preservation
no difference were found even in serum protein levels.
A significant difference was found in favour of Aboral Pouch in the number of
meals taken per day, but only at 6 months and then it equalised and even became better
in Oral Pouch patients at 24 months though not significantly.
The rest of the measured parameters – serum cholesterol, triglicerid,
haemoglobin, iron, transferrine saturation, transferrine, OPNI, SSBP, lipid and
carbohydrate absorption tests did not differ significantly between Oral and Aboral
Pouch patients.
In summary, the site of the reservoir when added to a duodenal passage
preserving reconstruction did not result in any major difference in the examined
parameters in the first two years after surgery.
Long Term Results of comparing Aboral Pouch, Aboral Pouch with Preserved
Duodenal Passage and simple Roux-en-Y reconstruction
Thirty-five patients were available at least 3 years – twenty-three 3 years, eight 4
years, three 5 years and one 6 years - after surgery. The average follow-up was 3,48
years after total gastrectomy. Thirteen patients from AP, twelve from APwPDP and ten
from RY groups attended for long term examinations.
Anthropometric measurements: The body weight, BMI as well as change in
BMI in percentage of the postoperative BMI did not differ among the groups at the long
term check-up (table 3). Patients in APwPDP group gained the most weight, their BMI
was 7% higher than postoperatively, but the difference between the groups was not
significant.
Table 3: Long term results: In the long run significant differences were found between
the groups in small bowel passage and the number of meals taken per day. P values for
ANOVA are represented. Post hoc test results revealing the source of difference are
detailed in the text.
Long Term AP APwPDP RY p
n: 13 12 10
Body weight 73,10 ± 7,92 61,70 ± 2,21 66,80 ± 5,41 0,24
BMI 24,91 ± 2,30 22,36 ± 0,75 24,74 ± 1,21 0,32
BMI % 103,69 ± 4,32 107,88 ± 4,87 98,75 ± 4,82 0,43
Protein 77,00 ± 1,75 73,72 ± 1,27 73,34 ±2,10 0,23
Albumin 44,86 ± 0,77 43,97 ± 0,64 43,54 ± 1,01 0,51
Triglicerid 1,69 ± 0,38 1,51 ± 0,25 1,22 ± 0,16 0,62
Cholesterol 5,57 ± 0,37 5,00 ± 0,18 4,96 ± 0,29 0,25
Hemoglobin 135,77 ± 2,57 134,64 ± 2,56 131,71 ± 6,66 0,75
Iron 20,14 ± 2,53 24,15 ± 2,54 19,9 ± 2,90 0,43
Transferrine saturation % 27,86 ± 7,62 33,13 ± 18,15 23,48 ± 5,82 0,79
Transferrine 2,68 ± 0,12 2,98 ± 0,09 2,24 ± 0,22 0,36
IgA 3,88 ± 0,69 3,07 ± 0,46 2,43 ± 0,52 0,27
IgG 12,83 ± 1,11 11,40 ± 0,97 10,91 ± 1,06 0,45
IgM 2,15 ± 0,40 1,37 ± 0,19 1,36 ± 0,57 0,22
OPNI 55,13 ± 1,56 55,38 ± 1,17 51,38 ± 1,69 0,21
GIQLI 94,38 ±6,86 96,20 ± 6,53 94,6 ± 9,64 0,98
SSBP 0,92 ± 0,14 0,54 ± 0,08 0,76 ± 0,13 0,04
Lipiodol 4,06 ± 0,83 4,49 ± 0,41 4,42 ± 0,58 0,78
Xylose 843,5 ± 186 1036,2 ±157 1133,8 ± 306 0,61
Number of meals / day 4,25 ± 0,41 4,30 ± 0,26 6,80 ± 0,49 0,0001
Nutritional and immunologic laboratory measurements: In the long term no
difference could be detected in the examined laboratory parameters - i.e. serum total
protein, albumin, triglicerid, cholesterol, haemoglobin, iron, transferrine saturation,
transferrine, immunoglobulins and OPNI – among the three groups (table 3).
Scintigraphic small bowel passage study (SSBP): Small bowel passage
scintigraphy showed the slowest emptying rate in patients with APwPDP reconstruction
in the long term too. The difference for the three groups was significant (ANOVA p =
0,04), post hoc comparison revealed significant difference between AP and APwPDP
being responsible for it (p = 0,029).
Lipid and carbohydrate absorption tests: No reconstruction dependent difference
has been detected regarding lipid and carbohydrate absorption in the long term (table 3).
Quality of Life: Result of the gastrointestinal quality of life test did not reveal
any significant difference among the three groups. The number of meals taken per day
however still differed in favour of reconstructions with a pouch (ANOVA p = 0,0001,
post hoc comparisons: RY versus AP p =0,0001, RY versus APwPDP p = 0,0001).
Discussion
Most of the differences seen in comparing these three reconstruction types
disappeared in the long term, as it could have been judged already from the 24 months
data. No advantage was gained from aboral pouch construction in the long term, apart
from the lower number of meals taken per day, but it did not translate into a gain in the
quality of life. Duodenal passage preservation did not yield an advantage in nutritional
or quality of life parameters, neither in the long term, nor in absorption of lipids,
however a favourable rate of emptying – i.e. a slower emptying rate – remained as an
advantage even after 3 years postoperatively.
Long term follow-up of randomised population of different reconstructions after
total gastrectomy are rare. Ivonen et al reported better quality of life in pouch patients
compared to Roux-en-Y 5 years after surgery. Kono et al found better quality of life and
less bile reflux in cases of pouch construction compared to simple Roux-en-Y
reconstruction 4 years after surgery. Mochiki et al described a favourable motility
pattern and a better food intake (volume per meal) for Longmire interposition,
compared to oral pouch interposition 44 months after total gastrectomy.
Long term follow-up showed, that - apart from a favourably slower transit with
preserved duodenal passage and lower number of meals with pouch construction - no
long lasting advantage can patients expect from a more complicated reconstruction. The
important advantages in lipid and iron metabolism and quality of life however, seen in
the first years after gastrectomy may give a very important nutritional support to these
patients in the fight of cancer in the most sensitive years, when recurrence is most
frequent. Although no data of ours or else supports this oncological advantage of
duodenal passage preservation or pouch construction yet.
Clinical Experiment on a Prospectively Randomised Patient Population to
Evaluate Postprandial Glucose, Insulin, Cholecystokinin and Somatostatin
response in patients after Total Gastrectomy and Aboral Pouch with Preserved
Duodenal Passage, Aboral Pouch or Roux-en-Y Reconstruction
Patients
Patients from the randomised patient population comparing Aboral Pouch (AP),
Aboral Pouch with Preserved Duodenal Passage (APwPDP) and simple Roux-en-Y
(RY) reconstructions, were recruited for gastrointestinal hormone measurements,
between year 1999 and 2001.
Eleven patients with AP, ten with APwPDP and seven with RY reconstruction
gave their consents to hormone stimulation test. Six healthy volunteers served as a
control group. The average age of the patients was 56,32 years, male to female ratio
19/15. Mean time elapsed after surgery was 16,54 months. Patients’ characteristics are
shown in table 4. The three patient groups were homogenous with regard to age, gender,
stage of disease and post surgical time. All but two patients were operated on for gastric
adenocarcinoma, one patient in AP group with gastrointestinal stromal tumor and one
with a fibrosarcoma of the stomach. These two patients’ disease stages are not shown in
table 4.
Table 4: Patients’ characteristics
AP APwPDP RY Normal p-value
Age (years) 54,27±2,6 58,8±5,1 62,43±2,8 48,83±7,1 0,264
Male:Female 6:5 5:5 4:3 4:2 0,935
Stage I/II/III 2/2/5 2/5/3 1/2/3 NA 0,704
Time after
surgery
(months)
19,18±3,4 12,30±2,0 18,43±4,7 NA 0,283
NA: not applicable
Hormone provocation test
After an overnight fast (12-15 hours) a liquid test meal (500 kcal; 70 g
carbohydrate, 36 g protein, 7 g fat) was administered at room temperature, in a sitting
position. Blood samples were taken 5 minutes before, and 15, 30 and 60 minutes after
ingestion of the test meal. One sample from each patient at each time was sent for blood
glucose analysis using the glucose oxidase method. Other sample, mixed with EDTA
and aprotinin, was collected on ice, centrifuged at 4 0C and the plasma stored at -30 0C
for later hormone analysis.
Radioimmunoassays for cholecystokinin, insulin and somatostatin
Plasma cholecystokinin concentration was measured by a commercial
cholecystokinin radioimmunoassay kit RK-069-04 (Phoenix Pharmaceuticals Inc
Belmont USA). The cholecystokinin antibody was raised against CCK octapeptide 26-
33 (non-sulfated). The sensitivity of the assay was 1 pg/tube. The CD50 for the
calibration curve was 35,44 pg/tube.
Plasma insulin concentration was measured by a commercial insulin
radioimmunoassay kit RK-400M (Institute of Isotopes Budapest Hungary). The insulin
antibody was highly specific for human insulin with cross-reactivity to human
proinsulin of 65%. The sensitivity of the radioimmunoassay was 5 μIU/ml, the inter-
assay variance 6,2%, the intra-assay variance was 7,1%.
Plasma somatostatin was measured by a specific and sensitive
radioimmunoassay developed at the Department of Pharmacology and
Pharmacotherapy, University of Pécs.
Results
Glucose
Glucose curve for controls seems flat, while for the operated patients reach
higher values. The curves look diabetoid, most prominently in RY patients. Factorial
analysis of variance found significant difference between the curves for the four groups.
Groups with duodenal exclusion (RY and AP) had significantly higher glucose levels
compared to the normal control group.
Insulin
The insulin level increased to abnormally high values in all three gastrectomised
groups in response to food stimulus, compared to healthy control. The basal values did
not differ between the four groups. The insulin curve ran highest in patients with
preserved duodenal passage (APwPDP). Factorial ANOVA showed that the curves
differed significantly according to the type of the groups. Post hoc comparisons showed
significant difference between normal and AP and normal versus APwPDP groups. The
integrated secretion was higher in the operated groups than in controls, however the
difference did not reach a significant level, probably because of the high standard
deviation of insulin data.
Cholecystokinin
Regarding this gastrointestinal hormone the examined groups separated to a
group with higher basal as well as stimulated values, incorporating patients with
duodenal exclusion (RY and AP patients) and to a group of lower values, including
APwPDP patients and the healthy controls. ANOVA analysis showed significant
difference between the curves according to reconstruction type. Post hoc comparisons
showed that all four groups differed significantly from each other except AP from RY.
For integrated cholecystokinin secretion RY and AP groups showed significantly higher
amount of secretion compared to normal, while data for APwPDP did not differ from
normal significantly.
Somatostatin
The control group for somatostatin reached peak value around 15 minutes and
the level decreased from that point. In patients with duodenal exclusion (RY and AP)
somatostatin level increased longer and further, almost twice as high as in normal
controls, until around 30 minutes postprandially, than seemed to reach a plateau in AP
patients, while start to decrease in RY. In patients with APwPDP reconstruction the
peak and plateau were at the same time like in AP group, however somatostatin level
did not reach much higher values than in control patients. The data sets differed
significantly regarding type of operation analyzed by factorial ANOVA. Post hoc tests
showed significantly higher values for AP compared to normal and for AP compared to
APwPDP, the rest of the groups did not differ significantly from each other. The
integrated secretions also differed significantly with higher values for AP and lower for
APwPDP and normal control groups. Postprandial curve for RY group ran between the
curves of AP and APwPDP, integrated secretion of somatostatin for RY patients were
also between this two groups’ results, but there were no significant difference of RY
data from any other groups most likely because of the high standard deviation in this
group.
Discussion
The whole problem of postgastrectomy symptoms might be attributed to the
accelerated intestinal transit. The rapid transit results in accelerated glucose absorption
bringing about higher output of insulin. Accelerated transport of peptides and lipids
gives an abnormally large stimulus to cholecystokinin production, magnified by the
brake in the feed back regulation. All ends in abnormally high gastrointestinal hormone
levels, which brings about increased production of somatostatin. And somatostatin will
arrest, as needed, this cascade of GI hormone production, but additionally reduces gut
motility and digestive juice production. The whole phenomenon probably becomes less
significant with time due to the intestinal adaptation. This hypothesis though needs
further evaluation.
In summary our experiment supports a diabetoid blood glucose profile in the
first postprandial hour in patients after gastrectomy and routine Roux-en-Y
reconstruction, with higher insulin concentrations, elevated cholecystokinin levels and
an increasing somatostatin release after 15-30 minutes postprandially. The creation of a
pouch seems not to improve much on this disturbed regulation. Duodenal passage
preservation however helps to moderate the postprandial cholecystokinin elevation and
results in a less steep postprandial plasma somatostatin curve, probably reflecting a
decreased need for arresting the abnormally high output of other gastrointestinal
hormones in these patients.
Our earlier data proved better quality of life in the first postoperative year for AP
compared to RY patients, and for APwPDP compared to both AP and RY. Long term
data have not been reported yet. This better life quality may at least partly come from
the differences in gastrointestinal hormone profile.
Weather these differences in gastrointestinal hormone production in favour of
duodenal passage preservation result in less compromise in appetite and hunger
sensation and are able to contribute to a less reduced caloric intake in patients after
gastrectomy, needs further evaluation. Furthermore, recently discovered hormones
involved in appetite and meal size regulation, such as ghrelin and leptins needs to be
examined in gastrectomized patients.
Examining the Presence of Biliary Reflux at Different Types of Reconstructions
after Total Gastrectomy
The manometry and Bilitec biliary reflux studies are still going on. Upper
endoscopy, esophageal manometry and 24 hour Bilitec examinations were carried out
for two patients with aboral pouch, five with aboral pouch with preserved duodenal
passage three with oral pouch with preserved duodenal passage and four with control
Roux-en-Y reconstruction. Further four patients are planned to be included before
analysis.
